TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Large Drop in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP – Get Rating) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 48,500 shares, a decline of 62.3% from the April 30th total of 128,500 shares. Based on an average trading volume of 319,000 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

Separately, HC Wainwright lowered their price objective on shares of TC Biopharm from $9.00 to $7.00 in a report on Thursday, April 27th.

TC Biopharm Trading Up 1.2 %

Shares of TCBP traded up $0.01 during mid-day trading on Friday, reaching $0.87. The company’s stock had a trading volume of 166,631 shares, compared to its average volume of 884,363. TC Biopharm has a 52 week low of $0.71 and a 52 week high of $41.48. The company’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $3.85.

Institutional Investors Weigh In On TC Biopharm

A number of hedge funds have recently made changes to their positions in the business. Armistice Capital LLC bought a new stake in TC Biopharm during the 4th quarter valued at $318,000. Virtu Financial LLC raised its holdings in TC Biopharm by 454.0% during the 3rd quarter. Virtu Financial LLC now owns 130,005 shares of the company’s stock valued at $35,000 after buying an additional 106,539 shares during the last quarter. Renaissance Technologies LLC raised its holdings in TC Biopharm by 581.7% during the 3rd quarter. Renaissance Technologies LLC now owns 146,400 shares of the company’s stock valued at $41,000 after buying an additional 124,925 shares during the last quarter. Finally, Legal & General Group Plc bought a new stake in TC Biopharm during the 2nd quarter valued at $76,000. 66.72% of the stock is currently owned by institutional investors.

TC Biopharm Company Profile

(Get Rating)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19.